European expert opinion on the management of invasive candidiasis in adults.

Détails

ID Serval
serval:BIB_E07440329754
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
European expert opinion on the management of invasive candidiasis in adults.
Périodique
Clinical Microbiology and Infection
Auteur⸱e⸱s
Kullberg B.J., Verweij P.E., Akova M., Arendrup M.C., Bille J., Calandra T., Cuenca-Estrella M., Herbrecht R., Jacobs F., Kalin M., Kibbler C.C., Lortholary O., Martino P., Meis J.F., Muñoz P., Odds F.C., De Pauw B.E., Rex J.H., Roilides E., Rogers T.R., Ruhnke M., Ullmann A.J., Uzun Ö., Vandewoude K., Vincent J.L., Donnelly J.P.
ISSN
1469-0691 (Electronic)
ISSN-L
1198-743X
Statut éditorial
Publié
Date de publication
2011
Volume
17
Numéro
Suppl. 5
Pages
1-12
Langue
anglais
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov't
Publication Status: ppublish
Résumé
This report discusses the present status of antifungal therapy and treatment options for candidaemia, considered by experts in the field in Europe. A conference of 26 experts from 13 European countries was held to discuss strategies for the treatment and prevention of invasive candidiasis, with the aim of providing a review on optimal management strategies. Published and unpublished comparative trials on antifungal therapy were analysed and discussed. Commonly asked questions about the management of candidaemia were selected, and possible responses to these questions were discussed. Panellists were then asked to respond to each question by using a touchpad answering system. After the initial conference, the viewpoint document has been reviewed and edited to include new insights and developments since the initial meeting. For many situations, consensus on treatment could not be reached, and the responses indicate that treatment is likely to be modified on a patient-to-patient basis, depending on factors such as degree of illness, prior exposure to azole antifungals, and the presence of potentially antifungal drug-resistant Candida species.
Mots-clé
candida, candidaemia, consensus, guidelines, therapy, INTENSIVE-CARE-UNIT, LIPOSOMAL AMPHOTERICIN-B, CRITICALLY-ILL PATIENTS, EMPIRICAL ANTIFUNGAL THERAPY, PLACEBO-CONTROLLED TRIAL, NON-ALBICANS CANDIDEMIA, DOUBLE-BLIND TRIAL, SURGICAL-PATIENTS, PERSISTENT FEVER, ANTIMANNAN ANTIBODIES
Pubmed
Web of science
Open Access
Oui
Création de la notice
29/09/2011 10:02
Dernière modification de la notice
20/08/2019 17:04
Données d'usage